Separator

Neuroscience Startup 'BrainSight AI' uplifts $5 million Funding from IAN Alpha Fund & Others

Separator
BrainSight AI, a deep tech neuroscience startup, has raised $5 million in a Pre-Series A funding round led by IAN Alpha Fund. Silver Needle, IvyCap Ventures, and the company's current investors also participated.

Prior to this, the Bengaluru-based company had raised $925K from Pfizer and other sources.

According to a press release from BrainSight, the new funding will be used to develop R&D capabilities, broaden the company's reach in Tier I and Tier II cities, penetrate new markets in the US, Africa, Southeast Asia, and other allies, and increase its presence in India.

BrainSight claims that some of its platform products are Snowdrop, a patient care app that facilitates adherence to treatment plans and creates patient profiles, and Voxelbox, which gives clinicians access to an fMRI processing engine and machine-learning models.

BrainSight AI, which was Co-founded in 2019 by Laina Emmanuel and Rimjhim Agrawal, seeks to improve the accuracy of neuro-oncological and neuropsychiatric disease diagnosis and treatment planning. Through the use of artificial intelligence and neuroscience, the platform expedites patient outcomes by enabling precision in neurological and psychiatric investigations.

As of right now, BrainSight AI claims to work with more than 40 top hospitals in India, specializing in radiology and neurosurgery departments for brain tumor cases. In order to support a more comprehensive approach to brain care, the company is now broadening the range of neurological and psychiatric disorders for which it offers solutions.

By mapping the brain's macro-scale neural connections, BrainSight AI contributes to our understanding of how the physiology and functions of the brain interact to enable accurate diagnosis and prognosis of neuropsychiatric and neuro-oncological disorders.